Literature DB >> 18547964

Polo-like kinase 1 as a new target for non-Hodgkin's lymphoma treatment.

Lin Liu1, Min Zhang, Ping Zou.   

Abstract

OBJECTIVES: The study was devised to detect expression of polo-like kinase 1 (PLK1) in non-Hodgkin's lymphoma (NHL) and assess its value as a new target for NHL treatment.
METHODS: The expression of PLK1 in NHL was detected by immunohistochemical techniques. Lymphoma cells were transfected with RNA interference plasmid targeted against PLK1 gene. Western blot was used to examine PLK1 expression in transfected cells. Proliferation, cell cycle and apoptosis were monitored by MTT and flow cytometry.
RESULTS: The expression rate of PLK1 in NHL was 63.6% (56/88). In B cell NHL and T cell NHL, PLK1 expression had relationships with systemic symptom, lactate dehydrogenase level and International Prognostic Index scores. PLK1 overexpression was associated with shortened event-free survival and was an independent prognostic factor for NHL. PLK1 depletion by RNA interference plasmid in lymphoma cell lines could lead to cell growth suppression, cell cycle arrest and apoptosis induction.
CONCLUSIONS: PLK1 overexpression is an adverse predictive factor in NHL and PLK1 could be a new therapeutic target for NHL. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18547964     DOI: 10.1159/000139137

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  5 in total

1.  Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

Authors:  Barbara Peter; Karoline V Gleixner; Sabine Cerny-Reiterer; Harald Herrmann; Viviane Winter; Emir Hadzijusufovic; Veronika Ferenc; Karina Schuch; Irina Mirkina; Hans-Peter Horny; Winfried F Pickl; Leonhard Müllauer; Michael Willmann; Peter Valent
Journal:  Haematologica       Date:  2011-01-17       Impact factor: 9.941

Review 2.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Authors:  Klaus Strebhardt
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

Review 3.  Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.

Authors:  Ion Cristóbal; Federico Rojo; Juan Madoz-Gúrpide; Jesús García-Foncillas
Journal:  Mol Cell Biol       Date:  2016-05-31       Impact factor: 4.272

4.  The expression of PLK-1 in cervical carcinoma: a possible target for enhancing chemosensitivity.

Authors:  Yuan Zhang; Yu Liu; Yuan-Xian Yang; Jia-Hong Xia; Hong-Xiu Zhang; Hua-Bin Li; Chun-Zhao Yu
Journal:  J Exp Clin Cancer Res       Date:  2009-09-23

5.  The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis.

Authors:  Hefei Li; Haibo Wang; Zhenqing Sun; Qiang Guo; Hongyun Shi; Youchao Jia
Journal:  Biosci Rep       Date:  2017-07-19       Impact factor: 3.840

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.